CARsgen Therapeutics Appoints President of U.S. Ops

CARsgen Therapeutics Holdings Ltd., a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has appointed Richard John Daly as President of CARsgen Therapeutics Corp., a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Ltd.

Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, business development, commercialization, investor relations and public relations. Mr. Daly will also contribute to the overall growth strategies and business planning of CARsgen, helping the Company to develop more innovative cell therapies to cancer patients.

Mr. Daly brings approximately 30 years of experience in the pharmaceutical industry, including leadership positions in multi-national corporations and biotech companies. Prior to joining CARsgen, Mr. Daly served as Chief Operating Officer of Beyond Spring, Inc. From February 2016 to July 2018, Mr. Daly served as Chief Executive Officer, President and Chairman of Neuralstem, Inc. Mr. Daly served in AstraZeneca as the President of the U.S. Diabetes subsidiary (formerly BMS-AZ Diabetes Alliance). From 1998 to 2011, Mr. Daly served at Takeda and TAP Pharmaceuticals, a joint venture established between Takeda and Abbott Laboratories, holding several leadership positions, including the Executive Vice President at Takeda Pharmaceutical North America and the Senior Vice President of marketing at TAP Pharmaceuticals. Mr. Daly currently sits on the boards of directors of Catalyst Pharmaceuticals and Opiant Pharmaceuticals.

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We warmly welcome Mr. Daly to join CARsgen. The breadth of Mr. Daly's experiences in sales and marketing, business development, and operation management makes him an ideal fit to lead the team of our U.S. subsidiary. Mr. Daly joins us at an exciting time of the company's accelerating growth and development, and it resonates with our ambition for the global markets. The joining of Mr. Daly will further accelerate our international business activities, including clinical development, CMC operation, business development, etc. Together with Mr. Daly and the team, we are committed to developing more innovative cell therapies to cancer patients worldwide and make cancer curable."